Novartis announced results from the COMBI-d and COMBI-v clinical trials, concluding first-line treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) offers both overall and progression-free long-term survival benefits to patients with unresectable or metastatic BRAF-mutation positive melanoma.
Genentech announced results from the pivotal phase III CLL14 study in previously untreated chronic lymphocytic leukemia showing Venclexta (venetoclax) plus Gazyva (obinutuzumab) met its primary endpoint of investigator-assessed progression-free survival.
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, Keytruda.
Bristol-Myers Squibb Co. announced first results from the Opdivo (nivolumab) plus Yervoy (ipilimumab) cohort of the phase I/II CheckMate-040 study, evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Results of a phase II clinical trial conducted at MD Anderson Cancer Center revealed combination targeted therapy, consisting of rituximab, lenalidomide, and ibrutinib, had an 84.6% overall response rate and 38.5% complete response rate when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma.
Astellas Pharma Inc. and Seattle Genetics Inc. announced data from the first cohort of a pivotal phase II clinical trial known as EV-201 demonstrated the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125; 95% Confidence Interval: 35.1-53.2).
A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective, new therapy for people with a specific type of advanced melanoma.
Taiho Oncology Inc. and Servier announced clinical data with Lonsurf (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer, metastatic gastroesophageal junction adenocarcinoma, and metastatic colorectal cancer were presented at the 2019 ASCO Annual Meeting.
Early-onset colorectal cancer is rising most rapidly in Western states, where healthy behaviors are prominent, according to a new study from the American Cancer Society and Ohio State University. The authors of the study, which appears in JNCI, say the findings indicate the need for further etiologic studies to explore early-life colorectal carcinogenesis.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed a blood test that can detect the presence of seven different types of cancer by spotting unique patterns in the fragmentation of DNA shed from cancer cells and circulating in the bloodstream.